

8. Guo DC, et al. MicroRNA-29b reduces mutant alpha-actin crystal aggregation and inhibition of equilibrative nucleoside transporter by dipyridamole may have therapeutic potential in ischemic acute kidney injury, a condition for which there are currently no specific therapeutic interventions. 

9. Zhu L, et al. Mutations in myosin heavy chain 11 are associated with 40%–70% mortality in the underlying pathogenesis and new therapeutic targets continue to be needed. 


Preserving postischemic perfusion in the kidney: a role for extracellular adenosine

Joel M. Weinberg¹ and Manjeri A. Venkatachalam²

¹Division of Nephrology, Department of Internal Medicine, Veterans Affairs Ann Arbor Healthcare System and University of Michigan, Ann Arbor, Michigan, USA. ²Department of Pathology, University of Texas Health Science Center (UTHSC) at San Antonio, San Antonio, Texas, USA.

Several adenosine receptor subtypes on endothelial, epithelial, mesangial, and inflammatory cells have been implicated in ischemic acute kidney injury, a life-threatening condition that frequently complicates the care of hospitalized patients. In this issue of the *JCI*, Grenz and coworkers provide novel insight into how preservation of postischemic perfusion by endothelial cell adenosine A2B receptors is antagonized by adenosine reuptake into proximal tubule cells by equilibrative nucleotide transporter 1, which can be inhibited by dipyridamole. The work suggests that adenosine A2B receptor agonists and inhibition of equilibrative nucleoside transporters by dipyridamole may have therapeutic potential in ischemic acute kidney injury, a condition for which there are currently no specific therapeutic interventions.

Acute kidney injury (AKI) is a life-threatening condition that frequently complicates the care of hospitalized patients. It is clinically defined by an abrupt reduction in renal clearance function (as typically measured by an increase in serum creatinine) and, when associated with structural damage to the renal parenchyma, can be prolonged, require dialysis support prior to recovery, and eventuate in chronic kidney disease even if recovery from the acute insult occurs (1, 2). While AKI can have multiple etiologies, ischemia is common to many of them (1) and predictably occurs in settings such as coronary bypass, where up to 7%–10% of patients develop AKI, which has been associated with 40%–70% mortality in the smaller cohort that requires dialysis and with increased subsequent long-term mortality even if dialysis is not needed (3).

Despite intensive research efforts and identification of multiple approaches effective in experimental models, there are no specific therapeutic interventions for treatment of AKI other than renal replacement therapy. Several targeted therapies have been tested in the clinic, but thus far all have failed (4). Both a better understanding of the underlying pathogenesis and new therapeutic targets continue to be needed. In this issue of the *JCI*, Grenz et al. elucidate a role for the equilibrative nucleoside adenosine A2B receptors in preserving postischemic renal function (5). If the phenomena observed in mice hold true in humans, these data have important therapeutic implications, as they suggest that modulating adenosine levels via effects on adenosine A2B receptor (Adora2b) on endothelial cells might be of benefit in individuals with AKI.

Generation of adenosine during AKI and its multiple potential effects

Changes in purine nucleotide metabolism are a hallmark of tissue oxygen deprivation (6). Within cells, failure to maintain ATP production due to limitation of oxidative phosphorylation and compensatory
anerobic glycolysis leads to the degradation of ATP, eventually to its nucleoside components. Both purine nucleotides and nucleosides are released from tissue parenchymal cells and circulating cells to the extracellular space, where they activate cell surface receptors (7, 8) and can undergo further metabolism by cell surface enzymes that convert ATP and ADP to AMP (9) and then AMP to adenosine (8). Extracellular adenosine modulates multiple physiological processes. Its effects are mediated via four distinct G protein-coupled receptors, the A1 adenosine receptor (Adora1), the A2A adenosine receptor (Adora2a), Adora2b, and the A3 adenosine receptor (Adora3). Activation of several of these receptors has been shown to play a major role in the response to injury in multiple tissues, including the response to oxygen deprivation (7).

In the kidney, adenosine produced by epithelial cells of the macula densa, a group of modified epithelial cells in the distal convoluted tubule, in response to solute delivery is centrally involved in the regulation of glomerular filtration rate (GFR) (10, 11). The net effect of adenosine in this process is to decrease GFR, primarily by stimulating vasoconstriction of afferent arterioles by activation of Adora1 on extraglomerular mesangial cells (10, 11), but recent work also suggests a contribution to the decreased GFR of vasodilation produced by efferent arteriolar Adora2b (12). Promotion and amelioration of AKI through the effects of adenosine on several of its receptors have been reported. Adora1-mediated afferent arteriolar vasoconstriction has been implicated in the suppression of GFR during AKI (10), but protective effects of activation of Adora1 on epithelial cells have also been documented (13). Adora2a on both neutrophils and T cells has potent, protective, anti-inflammatory effects (14). Adora2b has been shown to be necessary for ischemic preconditioning in the kidney (15).

Modulation of endothelial Adora2b activation by proximal tubule adenosine transport

In this issue of the JCI, Grenz et al. elegantly and comprehensively reveal a new dimension to the role of adenosine during AKI by showing that adenosine can protect from ischemic AKI in the mouse by preserving peritubular capillary blood flow during reperfusion (5). They find that adenosine mediates this effect by activating Adora2b on endothelial cells, which is opposed by adenosine uptake by equilibrative nucleoside transporter 1 (Ent1) at the basolateral surface of proximal tubules (Figure 1).

Grenz et al. used multiple pharmacological and genetic approaches to convincingly demonstrate an effect of this pathway in their model that exceeds the effects of other reported actions of adenosine during AKI. Treating mice with dipyridamole, a nonspecific Ent inhibitor, prior to initiation of ischemic AKI increased extracellular levels of adenosine in the kidney and protected against the functional and structural changes caused by ischemia. The benefit of dipyridamole was abolished by selective deletion of the gene encoding Adora2b in vascular endothelial cells, but not by deleting Adora1, Adora2a, or Adora3. Deletion of Adora2b in proximal tubule cells failed to abolish the protective effects of dipyridamole. Increasing the availability of extracellular adenosine by deleting the gene encoding Ent1 also was protective. Deleting Ent2 had no effect. The beneficial effect of Ent1 deletion could be reversed by kidney-specific lentiviral transduction with human ENT1. Consistent with involvement of tubule cell Ent1, studies with chimeric mice localized the effects of Ent1 to radiation-resistant tissue cells rather than hematopoietic cells. Kidneys protected by adenosine activation of Adora2b displayed less tissue hypoxia and strikingly improved recovery of renal blood flow by ultrasound and intravital microscopy in the immediate postischemic period, which appears to largely account for the benefit observed.

Sources of adenosine for Adora2b activation

An interesting question raised by the work of Grenz et al. (5) is, what is the source of the adenosine? The endothelial cells themselves, tubule epithelial cells, and intravascular leukocytes and platelets are all possibilities (refs. 7, 8, 10, and Figure 1). The pool of nucleotides in tubule epithelial cells is particularly large because of the relative mass of those cells, and intact nucleotides can leak from these cells to the extracellular space (16), likely via connexin hemichannels that open during ischemia (17). Upon leakage from tubule epithelial cells, extracellular AMP can be converted to adenosine by the eco-S′-nucleotidase CD73, which is highly expressed on interstitial pericytes, but not on the peritubular capillary endothelium (18). Metabolism of extracellular ATP and ADP requires the eco-nucleoside 5′-triphosphate diphosphohydrolase CD39, which is not found on pericytes but is present on the peritubular capillary endothelium (5). Alternatively, adenosine formed within tubule epithelial cells could exit via Ent1 or other pathways during ischemia. Adenosine could also derive from endothelial cells themselves or from intravascular neutrophils or platelets via release of ATP followed by its sequential metabolism via CD39 and CD73, both of which are present on neutrophils (7). Irrespective of the source, the data provided by Grenz et al. (5) are clear in showing that Ent1 in the tubule basolateral membrane effectively competes for adenosine with Adora2b to almost completely prevent Adora2b activation. Polyethylene glycol-modified adenosine deaminase, which should initially be confined to the vascular space, also completely prevented the protective effect of increasing extracellular levels of adenosine with dipyridamole (5). Thus, adenosine availability to endothelial Adora2b is sensitively regulated by both intravascular and extravascular processes that decrease its concentration.

Tubule cells use both concentrative and equilibrative nucleoside transporters for uptake of nucleosides (10, 19). However, the concentrative transporters are in the apical brush border membrane, so they do not impact the adenosine movements relevant for the regulation of Adora2b activity elucidated by Grenz et al. (5). Adenosine reuptake from the extracellular space by Ent1 is potentially desirable for epithelial metabolic recovery following reperfusion because restoration of intracellular adenosine nucleotides from nucleosides is energetically more favorable than de novo synthesis and is more effective from adenosine than from inosine or subsequent metabolites (19). The data provided by Grenz et al. (5), however, show that this adenosine reuptake opposes Adora2b-mediated protection of the endothelium and promotion of reperfusion and the latter effects are most important for the overall tissue response. The downregulation of Ent1 by ischemia and hypoxia also described by Grenz et al. (5) would favor these vascular protective effects of adenosine.

Role of Adora2b as opposed to other adenosine receptors

Another notable aspect of the work of Grenz et al. (5) is the complete dependence of the benefit of increasing adenosine either using dipyridamole or through Ent1 deletion on the presence of Adora2b, which
Figure 1
Sites of interacting processes in Adora2b-mediated protection against AKI. During ischemia, adenine nucleotides and adenosine can theoretically be released from tubule cells, endothelial cells, leukocytes, or platelets. Released ATP and ADP can be converted to AMP by CD39 on either endothelial cells or leukocytes (polymorphonuclear leukocytes [PMNs]). The released AMP can be further metabolized to adenosine by CD73, which in the kidney is most highly expressed on pericytes. CD73 is also expressed on leukocytes. In this issue of the JCI, Grenz et al. clearly show using mutant mice that activation by adenosine of Adora2b localized to the endothelium can preserve peritubular capillary blood flow that protects the tissue during reperfusion (5). Normally, despite the multiple potential extravascular and intravascular sites of adenosine generation, endothelial Adora2b activation is largely prevented by adenosine reuptake into proximal tubule cells by Ent1. Dipyridamole blocks Ent1-mediated adenosine reuptake and enables protective Adora2b activation. The large mass of proximal tubule cells as a source of released nucleotides and adenosine, the positioning of CD73 on pericytes to generate adenosine from nucleotides released by the tubules, and the sensitivity of adenosine availability to tubule cell Ent1 suggest that tubular cell adenosine generation is more important than intravascular for Adora2b activation. ADO, adenosine.
would seem inconsistent with the anti-inflammatory effects of adenosine mediat-ed by Adora2a (14) and the well-documented protective effects during AKI that have also been demonstrated for Adora1 in the mouse (13). Maintaining higher adenosine levels with dipyridamole or Ent1 deletion should also have promoted the latter two pathways. Grenz et al. attribute the apparent lack of effect on Adora1- and Adora2a-mediated pathways to the higher affinity of those receptors for adenosine (5), which allows their activation at lower adenosine levels than the levels reached with dipyridamole and Ent1 deletion and needed for activation of Adora2b. The Adora2b-mediated effects described by Grenz et al. clearly most strongly impact the immediate reflow period, and they tested dipyridamole and the Adora2b agonist PSB1115 only as a pretreatment or just before reflow. They did not test administration at later points. Promoting the anti-inflammatory effects of Adora2a on neutrophils and T cells (14) or the protective effects of Adora1 on parenchymal cells (13) could provide more possibilities for delayed interventions in the many translational settings in which pretreatment is not feasible. It is also conceivable that delayed activation of Adora2b after early reflow could be deleterious, for example, through proinflammatory stimulation of dendritic cells (20).

The strong benefit of dipyridamole reported by Grenz et al. (5) differs from previous work in the rat, where dipyridamole was shown to aggravate clamp ischemia–induced AKI (21). These divergent observations may relate to species differences or could be secondary to the mode of induction of ischemia. For most of their studies, Grenz et al. used a sling to constrict the renal artery, which appears to give highly reproducible results, but in this approach, the artery may occlude less completely than with the clamps used in the rat study and most other mouse work, so the insult in these other models may be more severe. In supplemental data, Grenz et al. (5) report work in which they induced a 20-minute insult using a bilateral clamp model of ischemic AKI and showed beneficial effects of dipyridamole and Ent1 knockout in terms of early recovery of GFR and improved histology, which could mean that longer durations are problematic and the benefit only occurs in a limited window of time.

Relevance to human AKI

The impaired posts ischemic reflow shown by Grenz et al. (5) to be alleviated by Ent1-sensitive Adora2b activation is well established to play a major role in the injury caused in small animal ischemia/reperfusion models (22–25). For technical reasons, Grenz et al. measured capillary perfusion in the superficial cortex, but it is more severely impaired in the deep cortex and outer medulla, where most structural damage develops (22–25). The authors have done service to the field by placing the complexities of adenosine transport and signaling in the context of reperfusion abnormalities. The translational relevance of their findings will depend on the role of reperfusion abnormalities during human AKI, which, as Grenz et al. point out, is largely unknown. Other maneuvers that have increased renal perfusion and alleviated AKI in small animal models, such as treatment with atrial natriuretic peptide, have failed in human trials (4). The relatively larger and more elongated medulla of rats and mice may predispose them to ischemic damage during reperfusion as compared with other species such as the dog and the human (22). Nonetheless, the striking nature of the findings in the work by Grenz et al., the clear delineation of the mechanism involved, and the availability of pharmacologic approaches that will be suitable for human application make translational testing of these findings appealing, particularly in settings where the insult can be anticipated and pretreatment is possible.

Acknowledgments

This work was supported by NIH grant DK-34275.